Celldex Reports Second Quarter 2015 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
Go back to Celldex Reports Second Quarter 2015 Results
August 11, 2015 10:10 AM EDT
Cantor Fitzgerald maintained a Buy rating on Celldex Therapeutics (NASDAQ: CLDX), and cut the price target to $31.00 (from $38.00), following its decision to delay BLA filing for Rintega. Analyst Mara Goldstein said that filing for Rintega is not likely until the completion of ACT IV. ACT IV is expected... More
August 11, 2015 7:07 AM EDT
Brean Capital maintained a Buy rating on Celldex Therapeutics (NASDAQ: CLDX), and cut the price target to $31.00 (from $35.00), following company talks with the FDA. CLDX has received enough feedback to conclude that it will not file Rintega for Accelerated Approval in recurrent GBM.
Analyst... More
August 11, 2015 6:58 AM EDT
Cowen maintained an Outperform rating on Celldex Therapeutics (NASDAQ: CLDX), and cut the price target to $28.00 (from $34.00), following 2Q earnings and clinical update. CLDX has decided not to file for acceleration of Rintega. Analyst Boris Peaker is disappointed by the rindo filing... More
August 10, 2015 4:51 PM EDT
Celldex (NASDAQ: CLDX) reported Q2 EPS of ($0.33), versus ($0.32) reported last year. Revenue for the quarter came in at $2.2 million, versus $592 thousand reported last year.
For earnings history and earnings-related data on Celldex (CLDX) click here.
...
More
